Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase 3 pivotal trial will evaluate zanzalintinib, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC)

Next Previous
Trial Profile

A randomized phase 3 pivotal trial will evaluate zanzalintinib, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanzalintinib (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STELLAR-316
  • Sponsors Exelixis

Most Recent Events

  • 16 Jan 2026 New trial record
  • 11 Jan 2026 According Exelixis media release, the company expects to initiate STELLAR-316 in mid-2026.
  • 07 Jan 2026 According Exelixis media release, the company announced their collaboration with Natera for this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top